Novartis starts a second Phase 2 trial of VAV1 degrader MRT-6160
Company / institutional announcement · Monte Rosa Therapeutics
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Monte Rosa announced that Novartis initiated a second Phase 2 study of the VAV1 molecular glue degrader MRT-6160, also called DDY391, in active moderate to severe psoriatic arthritis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, tolerability, and dose response. The first patient visit triggers a $37.5 million milestone payment.
Why it may matter
The trial broadens disease-level testing of VAV1 degradation and could help determine whether deep target depletion translates into useful autoimmune efficacy.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections